Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine
Intellia Therapeutics(NTLA) Newsfilter·2024-02-01 06:00NTLA-2002疗效 - NTLA-2002单剂量可显著减少HAE发作率，9名患者在16周观察期后仍完全无发作[1] - NTLA-2002在所有剂量水平下耐受性良好[1] NTLA-2002研究计划 - Intellia计划在2024年下半年启动NTLA-2002的全球关键性第三阶段研究[4]